Bempedoinsäure – ein neuer Spieler in der Lipidtherapie

Bempedoic acid—a new player in lipid therapy

This is a preview of subscription content, access via your institution.

Abb. 1


  1. 1.

    Pinkosky S, Newton R, Day E et al (2016) Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun 7:13457.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, Robinson PL, Ballantyne CM (2019) CLEAR harmony trial. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med 380(11):1022–1032

    CAS  Article  Google Scholar 

  3. 3.

    Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, Lalwani ND, Patel PM, Zhao X, Duell PB (2019) Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial. JAMA 322(18):1780–1788

    CAS  Article  Google Scholar 

  4. 4.

    Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, Kelly S, Stroes ESG (2019) Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc 8(7):e11662

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Prof. Dr. Holger Eggebrecht.

Ethics declarations


H. Eggebrecht gibt an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Eggebrecht, H. Bempedoinsäure – ein neuer Spieler in der Lipidtherapie. Kardiologe (2021).

Download citation